Compare T Rowe Price Group Inc (TROW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? T Rowe Price Group Inc trades at $107.71 (market cap $22.98B), while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: T Rowe Price Group Inc pays a 4.83% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, T Rowe Price Group Inc nearer its low. Which is the better fit depends on your goals.
| TROW | XBI | |
|---|---|---|
Market Cap | $22.98B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $121.68 | $169.55 |
52-Week Low | $86.19 | $93.43 |
Enterprise Value | $20.18B | — |
Dividend Yield | 4.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal and key support at $109. The stock shows strong profitability with a net margin of 29.26% and ROE of 20.1%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and ongoing AI adoption, positioning the firm for growth amid equity outflows.
The outlook is mixed: valuation metrics like a P/E of 10.99 suggest potential upside to the $111.67 consensus target, but bearish technicals and analyst caution (63% hold rating) indicate near-term headwinds. Risks include market-sensitive revenue and competitive pressures, though dividend stability and institutional buying support long-term value.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
